Paucibacillary leprosy

Summary

Paucibacillary leprosy (MONDO:0041752) is a disease. A subtype of leprosy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	paucibacillary leprosy
Mondo ID	MONDO:0041752
MeSH	D056005
ICD-11	1800264981
SNOMED CT	416483009
UMLS	C1562908
MedGen	288331
GARD	0025839
Is cancer (heuristic)	no

Also known as: paucibacillary leprosy · tuberculoid leprosy

Disease family

This is a subtype of leprosy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › leprosy › paucibacillary leprosy

Related subtypes (5): indeterminate leprosy, borderline leprosy, tuberculoid leprosy, lepromatous leprosy, multibacillary leprosy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.